GlassScriptPhysician profile
Marybeth Harper
NPI 1336807890
$2,924.93
in general payments reported to CMS, 2019-2025
18 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.18 · 2022: $765 · 2023: $584 · 2024: $933 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $593.56 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $510.52 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $442.71 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $206.60 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $184.69 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $143.28 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $142.49 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $121.67 | 2022-2024 | Qelbree |
| Axsome Therapeutics, INC. | $118.41 | 2024 | Auvelity |
| Avanir Pharmaceuticals, INC. | $90.03 | 2022 | |
| Ironshore Pharmaceuticals INC. | $65.85 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $62.80 | 2022-2025 | Invega Sustenna |
| Corium, LLC | $56.55 | 2023 | Azstarys |
| Almatica Pharma LLC | $51.69 | 2021-2022 | |
| Lundbeck LLC | $42.42 | 2022-2023 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.30 | 2022-2024 | Caplyta |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.54 | 2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $19.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marybeth Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.